OligoMedic, a manufacturer of osteoarthritis products, has announced that it will launch its JointRep product, an injectable implant designed to treat cartilage articular joint defects and reduce articular pain.
JointRep is a simple biocompatible, bioadhesive, approved for treatment of articular defect and could be used in knee, hip, ankle, wrist, elbow, shoulder, and extremities.
JointRep has the property to be liquid at room temperature and undergoes thermal phase transition to form a solid at body temperature, providing convenient and ease-of-use handling during arthroscopy.
The product has shown a significant reduction of Western Ontario and McMaster Universities (WOMAC) index score at six months, with a prolonged effect, to-date, up to 18 months in a clinical follow-up where patients have been treated under Canadian SAP.
JointRep is reportedly the first CE Mark approved product, and will be launched in Europe at the 51st National Congress SCIM in Rimini, Italy on 3 October 2013.
OligoMedic CEO Dr Amine Selmani noted the rationale behind JointRep development represents the fruit of the company's deep understanding and knowledge of physician/patient needs in reducing osteoarthritis pain and improving patient's quality of life.
"JointRep provides a significant added-value to 98% of arthroscopy procedures packed in a 3-minute procedural time," Dr Selmani added.
Currently, OligoMedic is expanding its product distribution to Italy, Belgium, Greece, Poland, Eastern-Europe, and Brazil, and is expanding its regulatory submissions to emerging markets such as Latin America, Asia and Middle East and North Africa.
